Skip to main content

Diabetic Patients

2
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Medica Corp
Medica CorpMA - Bedford
1 program
1
DLBS1449Phase 2/31 trial
Active Trials
NCT01972477Withdrawn0Est. Jan 2018
Dexa Medica
Dexa MedicaIndonesia - Tangerang
1 program
1
DLBS1449Phase 2/3
Takeda
TakedaTOKYO, Japan
1 program
TAK-875PHASE_33 trials
Active Trials
NCT01585792Completed80Est. Dec 2012
NCT01496443Completed28Est. May 2012
NCT00949091Completed60Est. Jul 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaTAK-875
Medica CorpDLBS1449
TakedaTAK-875
TakedaTAK-875

Clinical Trials (4)

Total enrollment: 168 patients across 4 trials

Double Blind Comparative Study of TAK-875

Start: May 2012Est. completion: Dec 201280 patients
Phase 3Completed

DLBS1449 in Diabetic Patients With Low HDL

Start: Jul 2016Est. completion: Jan 20180
Phase 2/3Withdrawn

TAK-875 Glimepiride Drug-Interaction Study

Start: Jan 2012Est. completion: May 201228 patients
Phase 1Completed

Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes

Start: Jan 2009Est. completion: Jul 200960 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.